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Abstract We have examined whether specific protein tyrosine 
kinase (PTK) inhibitors (genistein, tyrphostin, or geldanamycin) 
prevent nitric oxide (NO') production in rat smooth muscle cells 
(SMC), in murine brain endothelial cells (MBE), and in isolated 
rat aortas treated with endotoxin (LPS) and/or cytokines. 
Tyrphostin failed to inhibit either the release of nitrite in both 
endothelial and smooth muscle cells or vascular hyporeactivity in 
rat aorta, caused by immunostimulants. Genistein decreased 
nitrite production in MBE only at high concentration but had no 
effect on nitrite production in SMC and on the hypocontractility 
in aortic rings. In contrast, low concentrations of geldanamycin 
abolished the release of nitrite in MBE and in SMC treated with 
endotoxin and/or cytokines. Geldanamycin inhibited also the 
hypocontractility to phenylephrine in aortic rings treated with 
LPS or interleukin-1. This inhibitor failed to inhibit the release 
of nitrite and the vascular hyporeactivity once nitric oxide 
synthase (NOS) was induced by immunostimulants whereas 
methyl-L-arginine, an inhibitor of N O S , had significant effects. 
These data suggest that LPS- and cytokines-induced NO" 
production initiate a common signaling pathway involving a 
PTK that is inhibited by geldanamycin but not or slightly by 
tyrphostin or genistein at a point that precedes the induction of 
NOS. 
©1997 Federation of European Biochemical Societies. 
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1. Introduction 
Nitric oxide (NO") is involved as a signaling and effector 
molecule in several diverse biological systems [1]. Overproduc-
tion of NO" via the expression of an endotoxin- and cytokine-
inducible nitric oxide synthase (iNOS) in smooth muscle cells 
and endothelial cells of the vascular wall leads to an inappro-
priate vasodilatation in endotoxin shock [2,3]. The intracellu-
lar signals that regulate the expression of iNOS have been 
only partially characterized in a small number of cell types. 
Increases in intracellular cyclic A M P levels enhanced interfer-
on (IFN)-induced N O S expression in vascular smooth muscle 
cells [4] but partially reduced lipopolysaccharide (LPS)- and 
IFN-induced N O ' production in murine macrophages [5]. Pro-
tein kinase C appears to be involved with iNOS expression in 
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macrophages and hepatocytes [6,7], while in chondrocytes the 
activation of protein kinase C and protein kinase A is not 
sufficient to trigger iNOS expression [8]. Although both pro-
tein kinase C and protein kinase A have been implicated in 
mediating some effects of LPS in formation of inflammatory 
mediators, recent observations suggest that LPS activation 
operates independently from protein kinases C and A [8,9]. 
Tyrosine kinase inhibitors blocked LPS- or interleukin (IL-1)-
induced N O ' release in murine macrophages [10], pancreatic 
islet cells, and chondrocytes [8]. These inhibitors prevented 
both IL-1- and LPS-elicited cyclic G M P accumulation in vas-
cular smooth muscle cells [11] and had protective effects in an 
in vivo model of septic shock [12]. Thus, protein tyrosine 
kinases seem to be essential in immunostimulant-induced 
NO" production, suggesting that tyrosine kinases may be po-
tential targets to inhibit pathogenic effects of cytokines and 
LPS. Furthermore, it has been shown that the phosphorylated 
tyrosine can control gene expression by altering the activity of 
several transcription factors. We have investigated whether 
specific and chemically different protein tyrosine kinase inhib-
itors would prevent the production of N O ' induced by NOS in 
vascular smooth muscle cells, in murine brain endothelial 
cells, and isolated vessels stimulated with cytokines or LPS. 
2. Materials and methods 
2.1. Cell culture 
Vascular smooth muscle cells were kindly provided by Dr. Gross 
[13], Cells in passage 10-15 were seeded into 24-well plates for the 
measurement of nitrite production. MBE cells were kindly provided 
by Dr. Nicolson and cultured in gelatin-coated 96-well dished with 
100 |il culture medium until confluence. When cells reached conflu-
ence, the culture medium was aspirated and replaced with serum-free 
culture medium containing 0.1% (w/v) fatty acid-free bovine serum 
albumin to remove factors present in serum. The smooth muscle cells 
were exposed to IL-la (30 ng/ml), LPS (50 ng/ml)+IFN (500 IU/ml), 
or vehicle for 24 h in the presence or absence of tyrosine kinase 
inhibitors (geldanamycin, genistein, or tyrphostin) added 1 h before 
the NOS inducers. MBE cells were exposed to TNF (10 ng/ml)+IFN 
(500 IU/ml), or vehicle in the presence or absence of tyrosme kinase 
inhibitors added 1 h before cytokines. 
2.2. Nitrite assay 
Nitrite production, an indicator of NO' synthesis, was determined 
by colorimetrie assay. Aliquots of conditioned medium from confluent 
cells (50 ul) were mixed with an equal volume of Griess reagent (1% 
sulfanilamide and 0.1% W-(l-naphthyl)-ethylenediamine dihydrochlo-
ride in 2% phosphoric acid). Nitrite concentrations were determined 
by comparison with OD540 of standard solutions of sodium nitrite 
prepared in cell culture medium. 
2.3. Organ chamber studies 
Aortic rings were prepared from male Wistar rats (250-300 g) as 
described previously [14]. The rings were suspended in 10-ml organ 
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Fig. 1. Concentration-contraction curves evoked by phenylephrine in control (D) and immunostimulant-treated (■) rat aortic rings with endo-
thelium [IL-1 (40 ng/ml) (A) or LPS (100 ng/ml) (B)]. Effects of geldanamycin 0.1 uM (o), 0.5 uM (•), and 1 |J,M ( A ) on contractions evoked 
by this a-agonist in immunostimulant-treated rings (added 1 h before the induction). Results are presented as mean ± S.E.M. of five or six sepa-
rate experiments and are shown in absolute values. 
chambers under an optimal tension of 2.5-3 g. The tension was re-
corded with an isometric force transducer connected to an input 
board in an IBM 386/30 MHz personal computer. Rings were main-
tained at 37°C in Krebs-Ringer solution containing (composition in 
mM) NaCl, 118.3; KC1, 4.7; MgS04, 1.2; KH 2 P0 4 , 1.2; CaCl2, 2.5; 
NaHC03 , 25.0; CaEDTA, 0.016; and glucose, 11.1 (control solution). 
The presence of the endothelium was verified by the addition of ace-
tylcholine (10~6 M) in arteries contracted with phenylephrine (10~6 
M). The preparation were then rinsed three times with warm control 
solution, rested 30 min before a concentration-contraction curve to 
phenylephrine was obtained. To induce NOS activity, before suspen-
sion in the organ chambers aortic rings were incubated in 1 ml of 
DMEM/F12 containing IL-lcx (40 ng/ml), LPS (100 ng/ml), or vehicle 
for 5 h in the presence or absence of protein tyrosine kinase inhibitors 
added 1 h before the induction. 
2.4. Statistics 
Results are expressed as means ± S.E.M. Statistical evaluation of 
the data was performed by Student's /-test for paired or unpaired 
observations. P values less than 0.05 were considered significant. 
3. Results 
3.1. Release of nitrite 
Treatment of confluent cultures of smooth muscle cells 
from rat aortas with IL-1 (30 ng/ml) or LPS (50 ng/ml)+IFN 
(500 IU/ml) for 24 h caused the accumulation of nitrite in the 
incubation medium (Tables 1-3). Treatment of MBE cells 
with TNF (10 ng/ml)+IFN (500 IU/ml) also caused the release 
of nitrite (Tables 1-3). Exposure for 24 h to geldanamycin 
(0.01, 0.1, or 0.3 liM), genistein (1, 10, or 50 uM), or tyrphos-
tin (1, 10, or 50 uM) minimally affected the basal levels of 
nitrite anions in conditioned medium of unstimulated endo-
thelial or smooth muscle cells (data not shown). Geldanamy-
cin, added 1 h before the NOS inducer, elicited a concentra-
tion-dependent and significant inhibition of IL-1- and 
LPS+IFN-induced nitrite release of smooth muscle cells (Ta-
ble 1). In a similar manner, low concentrations of geldanamy-
cin (0.01, 0.03, or 0.1 uM) significantly inhibited NO' produc-
tion in culture medium of MBE cells treated with TNF+IFN 
(Table 1). When geldanamycin (0.1 u,M) was added 16 h after 
the inducers, the accumulation of nitrite was not significantly 
different in the presence or absence of this tyrosine kinase 
inhibitor (data not shown). The presence of genistein (1 uM 
or 10 |iM) slightly increased the accumulation of nitrite in the 
incubation medium of vascular smooth muscle cells stimu-
lated by IL-1 or LPS+IFN, while 50 uM of this inhibitor 
had no effect (Table 2). Only the high concentration (50 
uM) of genistein significantly reduced the release of nitrites 
induced by MBE cells treated with cytokines (Table 2). Sim-
ilarly, the release of nitrite stimulated by IL-1 was greater in 
the incubation medium of vascular smooth muscle cells in the 
presence than in the absence of tyrphostin (10 (tM) (Table 3). 
Tyrphostin (1 or 50 uM) failed to inhibit the effects of IL-1 
(Table 3). The pre-exposure of vascular smooth muscle cells to 
tyrphostin (1, 10, or 50 |a.M) was also associated with an 
increase of the accumulation of nitrite induced by LPS+IFN 
(Table 3). Pretreatment of MBE cells with tyrphostin (1, 10, 
or 50 |tM) did not change the release of nitrites of these cells 
stimulated with cytokines (Table 3). If methyl-L-arginine was 
included in the tissue culture medium, nitrites remained at 
Table 1 
Effects of increasing concentrations of geldanamycin (uM) on release of nitrite (uM) from MBE (1.5 X 104) and rat SMC (1.0 X 105) exposed to 
cytokines and/or endotoxin for 24 h 
MBE SMC SMC 
TNF+IFN 
+0.01 
+0.03 
+0.1 
47.7 ±5.8 
40.5 ±10.7 
26.0 ± 6.9 
1.0 ±0.6 
ILI 
+0.01 
+0.1 
+0.3 
19.3 ±3 
21.1 ±5.4 
2.3±0.1 
1.8±0.3 
LPS+IFN 
+0.01 
+0.1 
+0.3 
16.9±3 
19.2 ± 3 
1.9 ±0.4 
1.8 ±0.4 
Results are shown as mean ± S.E.M. of 3-5 separate experiments performed in triplicate. 
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Fig. 2. Concentration-contraction curves evoked by phenylephrine in control (n) and immunostimulant-treated (■) rat aortic rings with endo-
thelium [IL-1 (40 ng/ml) (A) or LPS (100 ng/ml) (B)]. Effects of genistein 1 uM (O), 10 |xM (•), and 100 uM ( A ) on contractions evoked by 
this oc-agonist in immunostimulant-treated rings (added 1 h before the induction). Results are presented as mean ± S.E.M. of five or six different 
experiments and are shown in absolute values. 
basal levels after LPS+IFN or IL-1 stimulation, in the pres-
ence or absence of tyrosine kinase inhibitors in smooth muscle 
cells (data not shown). 
3.2. Vascular reactivity 
The incubation of aortic rings with endothelium for 5 h in 
culture medium containing 40 ng/ml of IL-1 or 100 ng/ml of 
LPS shifted the concentration-contraction curves evoked by 
phenylephrine significantly to the right and decreased the 
maximal responses (Emax: control, 1.95 ±0.1 g; IL-1, 
1.14 ±0.18 g; LPS, 1.22 ±0.11 g) (Fig. 1). Treatment of aortic 
rings with geldanamycin (0.5 uM) or tyrphostin (100 uM) for 
6 h had no significant effects on contractions evoked by phen-
ylephrine (pEC50: 7.18±0.07 and 7.34±0.06 or 7.1 ±0.04 
without and with geldanamycin or tyrphostin, respectively) 
(£m a x : 2.08±0.13 g and 2.1 ±0.04 g or 1.9±0.04 g without 
and with geldanamycin or tyrphostin, respectively) while gen-
istein (100 |j.M) significantly decreased maximal responses to 
the ai-agonist (£1I1B: 1.4 ± 0.13 g in the presence of genistein) 
without changing the pECso (7.05 ±0.05). Geldanamycin (0.1 
|xM) added 1 h before IL-1 partially reversed the hyporeac-
tivity to phenylephrine and significantly increased the maxi-
mal responses from 1.14±0.18 g to 1.7±0.12 g (Fig. 1A). 
Higher concentrations of this inhibitor (0.5 uM and 1 |0.M) 
completely restored contractions evoked by this ai-agonist 
(Fig. 1 A). Treatment with a low concentration of geldanamy-
cin (0.1 |xM) induced a complete inhibition of the hypocon-
tractility to phenylephrine in rings incubated with LPS (Fig. 
IB). No additional inhibitory effects were obtained with high-
er doses of geldanamycin (0.5 uM or 1 |iM) (Fig. IB). In 
contrast, genistein or tyrphostin (1 (iM) did not affect the 
vascular hypocontractility induced by LPS or IL-1 (Figs. 2 
and 3) and 100 (iM of these inhibitors significantly potentiated 
the vascular hyporeactivity induced by cytokines or LPS 
(Figs. 2 and 3). When geldanamycin (0.5 \iM) was added 4 h 
after LPS or IL-1 into the culture medium, the contractions 
evoked by phenylephrine were not significantly different in the 
presence or the absence of this tyrosine kinase inhibitor 
(pEC50: IL-1, 6.81 ±0.08 and 6.73±0.07; LPS, 6.8±0.08 
and 6.79 ±0.07 without and with geldanamycin, respectively). 
4. Discussion 
These findings suggest that geldanamycin may interfere 
with the signaling process which induces NOS, by altering 
the activity of a protein tyrosine kinase at a point that pre-
cedes the induction of NOS and that protein tyrosine kinase 
activation may be involved in the induction of NOS expres-
sion by cytokines and endotoxin in endothelial or smooth 
muscle cells and isolated arteries. However, genistein and tyr-
phostin, two chemically distinct tyrosine kinase inhibitors, do 
not appear to be inhibitors of NOS since they failed to inhibit 
the NO' production in endothelial or smooth muscle cells and 
in isolated vessels induced with immunostimulants. 
The exposure of endothelial or smooth muscle cells to en-
dotoxin or cytokines for several hours was associated with the 
accumulation of nitrite in the incubation medium. These re-
sults indicate that mediators of immune and inflammatory 
responses stimulate the induction of NOS in vascular smooth 
muscle cells as well as in most other types of mammalian cells 
[15,16]. The observation that the release of nitrite caused by 
different cytokines or endotoxin in endothelial and smooth 
Table 2 
Effects of increasing concentrations of genistein (uM) on release of nitrite (|J.M) from MBE (1.5X 104) and rat SMC (1.0X 105) exposed to cyto-
kines and/or endotoxin for 24 h 
MBE 
TNF+IFN 
+ 1 
+ 10 
+50 
47.7 ±5.8 
53.0 ±8.0 
46.8 ±6.9 
28.3 ±6.7 
SMC 
ILI 
SMC 
14.4 ±1.3 
+ 1 16.1 ±2.1 
+ 10 20.8 ±3.2 
+50 13.4± 1.6 
S+IFN 
+ 1 
+ 10 
+50 
9.8 ±1.4 
17.6 ±3.3 
21.1 ±4.6 
10.5 ±1.6 
Results are shown as mean ± S.E.M. of 3-5 separate experiments performed in triplicate. 
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Fig. 3. Concentration-contraction curves evoked by phenylephrine in control (n) and immunostimulant-treated () rat aortic rings [IL-1 (40 ng/ 
ml) (A) or LPS (100 ng/ml) (B)]. Effects of tyrphostin 1 |xM (o), 10 |J.M (•), and 100 |lM ( A ) on contractions evoked by this a-agonist in im-
munostimulant-treated rings (added 1 h before the induction). Results are presented as mean ± S.E.M. of five or six separate experiments and 
are shown in absolute values. 
muscle cells is reduced in a dose-dependent manner by the 
pretreatment with geldanamycin, a potent and specific tyro-
sine kinase inhibitor [9,11], suggests that the induction and/or 
activity of NOS may be dependent on a tyrosine kinase. The 
stimulation of rat aortas for several hours with LPS or IL-1 
reduced their responsiveness to vasoconstrictors, as previously 
reported [14]. The fact that this vascular hypocontractility was 
completely inhibited by the presence of a tyrosine kinase in-
hibitor, geldanamycin, indicated the involvement of tyrosine 
kinases in the NO' synthesis induced by NOS. In addition, the 
regulatory mechanism involving protein tyrosine kinases is 
not restricted to a specific immunostimulant but functions 
during both IL-1 and LPS signaling. However, the ability of 
geldanamycin to inhibit IL-1- and LPS-induced NO" produc-
tion differs in its potency, reflecting a differential contribution 
of tyrosine kinases to the effects of LPS and IL-1. Further-
more, this agent does not appear to be an inhibitor of NOS 
since it failed to inhibit nitrite accumulation in vascular 
smooth muscle cells and the hypocontractility to vasoconstric-
tors once NOS was induced by LPS or IL-1; in contrast, 
methyl-L-arginine, an inhibitor of NOS [14], had significant 
effects. 
Thus, geldanamycin likely prevents the production of NO" 
in immunostimulant-activated endothelial cells, smooth 
muscle cells, and isolated arteries by inhibiting the expression 
of inducible nitric oxide. These results are in line with pre-
vious findings showing that the phosphorylated state of a 
tyrosine can control gene expression by altering the activity 
of several transcription factors [17]. The fact that previous 
studies [11] and our results showed that geldanamycin added 
after inducers exposure did not inhibit the NO' production 
suggests that tyrosine kinase inhibitors had no direct effect 
on iNOS activity after its induction and involvement of tyro-
sine activity is an early event. In contrast to geldanamycin, 
genistein and tyrphostin, two chemically distinct tyrosine kin-
ase inhibitors [8,9,11,18], do not or slightly alter the signaling 
process leading to the induction of NOS since they do not 
inhibit LPS- or IL-1-induced the release of nitrite in endothe-
lial and smooth muscle cells, or the vascular hypocontractility 
in isolated arteries. Doses of these two agents, which in pre-
vious studies inhibited cyclic GMP production in vascular 
smooth muscle cells [11] and nitrite production in macro-
phages [10] stimulated with IL-1 or LPS potentiated the ac-
cumulation of nitrite in vascular smooth muscle cells and the 
hyporeactivity to phenylephrine in aortic rings stimulated with 
cytokines or endotoxin in this study. These results in conjunc-
tion with those obtained with geldanamycin indicate that a 
specific tyrosine kinase susceptible to geldanamycin inhibition 
may be involved in LPS- and IL-1-mediated signal transduc-
tion. Among the possible targets for the tyrosine kinases are 
NF-kB/IkB complexes [21,22]. NF-kB is a critical transcrip-
tion factor of several genes that are involved in immune and 
inflammatory responses [23,24]. In addition, previous obser-
vations demonstrating that the promoter of mouse iNOS con-
tains at least two NF-kB sites [25] and that an inhibitor of 
NF-kB activation, pyrrolidine dithiocarbonate, abolished IL-
1-induced iNOS mRNA expression and NO' production in 
mesangial cells [26] are in line with our data and confirm 
that a tyrosine kinase may selectively participate in the signal-
ing pathway required for endotoxin and cytokines to induce 
the expression of iNOS to generate NO' production. Why the 
effects of genistein and tyrphostin on the modulation of NOS 
Table 3 
Effects of increasing concentrations of tyrphostin (uM) on release of nitrite (uM) from MBE (1.5 X104) and rat SMC (1.0 X 105) exposed to cy-
tokines and/or endotoxin for 24 h 
MBE 
TNF+IFN 
+ 1 
+ 10 
+50 
47.7 
47.5 
47.9 
46.1 
±5.8 
±6.3 
±6.8 
±7.4 
SMC 
ILI 
+ 1 
+ 10 
+50 
14.4 
14.3 
17.0 
12.8 
±1.3 
±1.7 
±3.1 
±2.4 
SMC 
LPS+IFN 
+ 1 
+ 10 
+50 
9.8 
17.8 
16.9 
12.8 
±1.4 
±3.2 
±3.3 
±3.5 
Results are shown as mean ± S.E.M. of 3-5 separate experiments performed in triplicate. 
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in this study differ from those seen in other reports is not 
clear, but differences in the types of cells or methods of stim-
ulation used might be responsible. However, previous reports 
support the finding that geldanamycin and its closely related 
analogue, herbimycin A, differ in their mechanism of action 
from genistein and tyrphostin [9,18]. Furthermore, there are a 
few da ta showing that the effects of genistein and tyrphostin 
might also result from some nonspecific action [19,20]. Gen-
istein may depress contraction in the swine carotid artery by 
altering intracellular calcium concentration [20] and increase 
production of IL-1 in macrophages [10], this could explain, in 
part, the potentiation of the effects of IL-1 and LPS in vas-
cular smooth muscle cells and in isolated arteries obtained in 
this study. 
These results demonstrate that protein tyrosine kinases are 
essential in the regulation of iNOS activity in vascular smooth 
muscle cells in murine brain endothelial cells, and in isolated 
vessels and that tyrosine kinase inhibitors may be useful in the 
treatment of diseases such as septic shock. However, except 
for geldanamycin, many commonly used protein tyrosine kin-
ase inhibitors failed to inhibit the induction of N O S . 
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